High Court To Tackle Novo Nordisk's Generic Drug Fight

Law360, New York (December 2, 2011, 7:23 PM EST) -- The U.S. Supreme Court on Monday will examine a Federal Circuit ruling limiting the power of generics makers to challenge patent information filed with the U.S. Food and Drug Administration, a ruling critics claim creates a loophole for brand-name drugmakers to improperly delay generic competition.

The high court will hear oral arguments in Caraco Pharmaceutical Laboratories Ltd. v. Novo Nordisk A/S, examining the question of whether a generic pharmaceutical company can challenge in court the accuracy of information a brand-name drugmaker files with the FDA used...
To view the full article, register now.